RecruitingNot Applicable

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Egypt30 participantsStarted 2022-01-01

Plain-language summary

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Who can participate

Age range

16 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age from 16 years and older.
. Gender: both sexes are included.
. Clinical Diagnosis of MG with supporting evidence as:
. unequivocal clinical response to pyridostigmine
. decrement \>10% in repetitive nerve stimulations study (RNS).
. Willingness to sample collection, imaging study and other disease-related examinations and assessments.

Exclusion criteria

. Age younger than 16 years.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in MG-specific Activities of Daily Living scale (MG-ADL).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG quality of life 15 (MG-QOL15).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG manual muscle testing (MG-MMT).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG composite (MGC) Score.

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Trial details

NCT IDNCT05214612

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Nourelhoda AA Haridy, Lecturer

01063981139 nourelhodaahmed@aun.edu.eg

View on ClinicalTrials.gov More Myasthenia Gravis trials

Plain-language summary

Who can participate

Age range

16 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age from 16 years and older.
. Gender: both sexes are included.
. Clinical Diagnosis of MG with supporting evidence as:
. unequivocal clinical response to pyridostigmine
. decrement \>10% in repetitive nerve stimulations study (RNS).
. Willingness to sample collection, imaging study and other disease-related examinations and assessments.

Exclusion criteria

. Age younger than 16 years.

What they're measuring

Change in MG-specific Activities of Daily Living scale (MG-ADL).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG quality of life 15 (MG-QOL15).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG manual muscle testing (MG-MMT).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG composite (MGC) Score.

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score